{
  "docId": "019de077-0cc2-77db-9351-9943b4f00de7",
  "docSlug": "7bc984921da16d0e07defb66ba0ce0a1",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 56 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 56,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes a biological process diagram showing the interaction between NXC-201 CAR-T cells and disease-causing LLPC clones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0cc2-77db-9351-9943b4f00de7/11",
  "deckHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7",
  "deckJsonHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7.json",
  "deckAnchorHref": "/decks/019de077-0cc2-77db-9351-9943b4f00de7#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.6,
        "x": 0.38,
        "y": 0.17
      },
      "kind": "diagram",
      "text": "Biological process flow from Plasma Cell to LLPC to NXC-201 interaction",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f809ae6-c0af-4679-8814-46ce6044f810",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.02,
        "y": 0.47
      },
      "kind": "list",
      "text": "AL Amyloidosis disease-causing plasma cells: Are a minority of total plasma cells; Are 1 of thousands of antibody-specific plasma cells; Are eliminated by NXC-201 treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "886b8401-651d-4255-8c0e-290ba62787b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "AL amyloidosis is caused by dysfunctional plasma cells that can live for years, continuously producing toxic, misfolded amyloid light chain antibody fragments",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42b2ede7-8026-4881-adce-c20dea4e45e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.02,
        "y": 0.75
      },
      "kind": "paragraph",
      "text": "Then healthy plasma cells regenerate in the months after NXC-201 treatment, potentially preventing disease relapse",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd62f2e9-1e22-4b64-86cc-939e5ff2f6e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 4th edition. New York: Garland Science; 2002. ...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e797e7f-88ea-4caf-85c4-0bdd8057f478",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.09
      },
      "kind": "title",
      "text": "ALL BCMA CAR-TS ARE NOT CREATED EQUAL",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cb4a663-8c6c-40c3-a125-4bc430f5af9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 May Be a Curative Treatment for AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "703365db-f618-4eeb-8b41-3c17b205d974",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "136cce28-0ccc-49c2-b966-521800f927cd",
      "evidence": "Diagram illustrates the causal link between NXC-201 and the elimination of disease-causing cells.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 7,
      "beatId": "47fc5325-813f-4c11-aad6-f3be9a635757",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 7-12: N-GENIUS Platform: Novel CAR-T Construct Drives Differentiated NXC-201 Clinical Profile; NXC-201 May Be a Curative Treatment for AL Amyloidosis",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "8f6d39a4-edc9-462c-b0f9-ba792c9a198d",
      "evidence": "Slides 9-15 highlight the limitations of current treatments and potential benefits of NXC-201",
      "position": 0,
      "objective": "What are the consequences of not adopting NXC-201?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}